Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (121-130 of 539) with videos related to

Pageof 54
Sort By:
Haematologica|June 13, 2012
Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myelomaJens Hillengass, Sofia Ayyaz, Kerstin Kilk, et al.
Haematologica|February 16, 2019
Quantitative dynamic <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myelomaChristos Sachpekidis, Maximilian Merz, Annette Kopp-Schneider, et al.
Experimental Hematology|February 15, 2011
Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environmentCaroline Bret, Dirk Hose, Thierry Reme, et al.
Oncotarget|May 10, 2014
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategyAlboukadel Kassambara, Claire Gourzones-Dmitriev, Surinder Sahota, et al.
Hematological Oncology|January 21, 2023
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myelomaJoseph Kauer, Lilli Sophie Sester, Katharina Kriegsmann, et al.
Blood Cancer Journal|August 27, 2024
Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significanceKosima Zuern, Thomas Hielscher, Annika Werly, et al.
EJNMMI Research|October 10, 2021
The prognostic significance of [<sup>18</sup>F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)Christos Sachpekidis, Maximilian Merz, Marc-Steffen Raab, et al.
Haematologica|March 26, 2017
Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysisMartin Granzow, Ute Hegenbart, Katrin Hinderhofer, et al.
International Journal of Cancer|April 10, 2020
B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectivesLeopold Sellner, Fuli Fan, Nicola Giesen, et al.
British Journal of Haematology|February 1, 2006
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myelomaAxel Glasmacher, Corinna Hahn, Florian Hoffmann, et al.
Pageof 54

Showing results (121-130 of 539) with videos related to

Sort By:
Pageof 54
Haematologica|June 13, 2012
Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myelomaJens Hillengass, Sofia Ayyaz, Kerstin Kilk, et al.
Haematologica|February 16, 2019
Quantitative dynamic <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myelomaChristos Sachpekidis, Maximilian Merz, Annette Kopp-Schneider, et al.
Experimental Hematology|February 15, 2011
Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environmentCaroline Bret, Dirk Hose, Thierry Reme, et al.
Oncotarget|May 10, 2014
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategyAlboukadel Kassambara, Claire Gourzones-Dmitriev, Surinder Sahota, et al.
Hematological Oncology|January 21, 2023
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myelomaJoseph Kauer, Lilli Sophie Sester, Katharina Kriegsmann, et al.
Blood Cancer Journal|August 27, 2024
Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significanceKosima Zuern, Thomas Hielscher, Annika Werly, et al.
EJNMMI Research|October 10, 2021
The prognostic significance of [<sup>18</sup>F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)Christos Sachpekidis, Maximilian Merz, Marc-Steffen Raab, et al.
Haematologica|March 26, 2017
Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysisMartin Granzow, Ute Hegenbart, Katrin Hinderhofer, et al.
International Journal of Cancer|April 10, 2020
B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectivesLeopold Sellner, Fuli Fan, Nicola Giesen, et al.
British Journal of Haematology|February 1, 2006
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myelomaAxel Glasmacher, Corinna Hahn, Florian Hoffmann, et al.
Pageof 54